1. To accept p16 IHC as a standalone test only in populations with a high prevalence of HPV and defining a threshold (e.g., 50%, which would be associated with (1-specificity) = 5% in the best case scenario, according to the above formula for the prevalence of HPV-driven OPSCC, above which the expected rate of false positive p16IHC is The accuracy of three possible test strategies was analysed: (a) hrHPV DNA PCR alone, (b) p16 (INK4a) IHC alone, and (c) the combination of p16 (INK4a) IHC and hrHPV DNA PCR; where positivity is defined by a co-positive result with both tests, a negative result by a co-negative result for both tests, and a discordant result by only one test Of the 1,896 women with normal cytology and HPV mRNA test (intervention group), 49 women (2.6%) had a positive test. The risks of CIN3+ among women with either a positive or negative HPV mRNA test were 28.6% (14/49) and 0.8% (14/1847). None of the women in the intervention group developed cervical cancer during follow-up. That is, women who test negative on the HPV test have an extremely low risk of developing cervical cancer. This finding, by researchers at the National Cancer Institute (NCI), part of the NIH, and their colleagues, appeared online July 18, 2014, in the Journal of the National Cancer Institute. HPV tests detect the DNA (or RNA) of the human Recently, the Human papillomavirus Deoxyribonucleic acid (HPV DNA) test is reported as having better accuracy than other methods. 14 However, it has been reported to have low specificity compared with cytology. 15 Those women who were screened and positive for HPV were more likely to be positive for VIA. 16 The clinical performance for the The HPV DNA test may be done during a Pap test. If they are done together, it is called "co-testing." You lie on a table and place your feet in footrests. Your health care provider inserts an instrument (called a speculum) into the vagina to open it slightly. This allows the provider to see the cervix. Cells are gently collected from the cervix This test utilizes transcription-mediated amplification (TMA) technology and detects mRNA from 14 high-risk HPV types associated with cervical cancer.4 Aptima detects HPV type 16 and HPV types 18/45 (18 is not differentiated from type 45).4 The cobas® HPV DNA Test This test utilizes an amplified molecular technology known as “polymerase Cervical biopsy, which is used in conjunction with Papanicolaou cytology testing, HPV DNA testing and colposcopy, has an important role in the evaluation and management of women with cervical dysplastic lesions. Thus, cervical biopsy is crucial for the prevention and early detection of cervical cancer . However, misinterpretation of The ASC-US/LSIL Triage Study (ALTS) is a clinical multicenter randomized study, sponsored by the National Cancer Institute, designed to compare three management options in ASC-US positive patients. The HPV-DNA test showed the most sensitivity and identified 96.3% (95% CI 91.6–98.8) of the women with CIN3+ [ 16 ]. NCI’s Cancer Information Service, or call 1-800-422-6237. Cervical screening test results usually come back from the lab in about 1-3 weeks. If you don't hear from your health care provider, call and ask for your test results. Make sure you understand any follow-up visits or tests you may need. kBKf.